Pasireotide Side Effects: What Studies Report

Pasireotide is a multi-receptor-targeted somatostatin analogue that has been studied mainly in two pituitary conditions: Cushing's disease and acromegaly. A pharmacology review described its mechanism of action and clinical applications, noting that its binding profile across several somatostatin receptor subtypes distinguishes it from earlier somatostatin analogues (PMID 29595102). That receptor breadth is also the reason its adverse-event profile, as reported in trials, differs from that of first-generation analogues (PMID 29595102).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, medication or treatment decision. The sections below summarise what researchers reported in published papers. Nothing here is a protocol, a monitoring plan or a recommendation.

Where the safety data come from

Most human safety information on pasireotide comes from registration and extension trials in pituitary disease, from systematic reviews, and from real-world cohorts. A 2026 Endocrine Reviews update on medical treatment of Cushing syndrome positioned pasireotide among pituitary-directed agents and discussed practical considerations for its use (PMID 41489578). A 2024 review of new trends in treating Cushing's disease also covered pasireotide within the medical-therapy landscape (PMID 39526050), and a 2023 evaluation of pharmacological options for Cushing's disease assessed where the drug sits among state-of-the-art choices (PMID 36927238).

In acromegaly, a long-term study of long-acting pasireotide reported on safety and efficacy over extended follow-up (PMID 34081309), and a multicentre, open-label, randomised phase 2 study evaluated long-acting pasireotide at 40 mg and 60 mg in Japanese patients with acromegaly or pituitary gigantism (PMID 28592706). Standards-of-care guidance from pituitary tumour centres of excellence addressed how second-generation somatostatin receptor ligands, including pasireotide, are positioned in medical management of acromegaly (PMID 38833044).

Glucose and Hyperglycemia: What Studies Report

Across the published literature, disturbance of glucose metabolism is the adverse effect most consistently linked to pasireotide. The long-term acromegaly study of long-acting pasireotide reported that hyperglycemia-related adverse events dominated the safety profile during extended treatment (PMID 34081309). Researchers in the Japanese phase 2 study likewise reported hyperglycemia-related events among the most frequent adverse events with the long-acting formulation (PMID 28592706).

In Cushing's disease, reviews have framed glucose elevation as a defining practical consideration of pasireotide therapy, because the underlying disease already carries a high background rate of glucose intolerance (PMID 41489578). A 2023 pharmacological evaluation discussed this trade-off when comparing pasireotide with other agents for Cushing's disease (PMID 36927238), and a 2024 review reached similar conclusions when surveying newer treatment trends (PMID 39526050).

The mechanistic explanation offered in the pharmacology literature relates to the drug's receptor-subtype profile and its effects on insulin and incretin secretion (PMID 29595102). A protocol for a systematic review and meta-analysis of pasireotide in Cushing's disease was registered specifically to pool efficacy and safety outcomes across trials, indicating that quantifying these events was considered an open question worth formal synthesis (PMID 33371162).

How glucose effects were handled in studies

Standards-of-care guidance for acromegaly discussed glucose monitoring as part of the management framework when second-generation somatostatin receptor ligands are used (PMID 38833044). Real-life data on pasireotide used as monotherapy or in combination in active Cushing's disease described how clinicians handled treatment in routine practice rather than in a trial setting (PMID 41323967). Neither publication is a set of instructions for an individual; both describe practice patterns reported by researchers.

Gastrointestinal Effects: What Studies Report

Gastrointestinal complaints are a class feature of somatostatin analogues, and the pharmacology review of pasireotide described the drug within that class context (PMID 29595102). In the long-term acromegaly study, gastrointestinal events were reported alongside glucose events as part of the overall tolerability picture during prolonged exposure (PMID 34081309). The Japanese phase 2 study of long-acting pasireotide also reported adverse events consistent with the known profile of the drug class (PMID 28592706).

Gallbladder and Hepatobiliary Findings: What Studies Report

Somatostatin analogues reduce gallbladder motility, and publications on pasireotide discuss biliary findings within the class safety profile (PMID 29595102). Long-term follow-up of long-acting pasireotide in acromegaly reported on safety over extended treatment periods, which is where cumulative biliary events would be captured (PMID 34081309). Acromegaly standards-of-care guidance from pituitary tumour centres of excellence addressed surveillance considerations that accompany long-term medical therapy (PMID 38833044).

Cortisol Lowering and Pituitary Hormone Effects: What Studies Report

Because pasireotide acts on corticotroph tumours in Cushing's disease, excessive cortisol reduction is a recognised consideration in the literature. The 2026 Endocrine Reviews update on medical treatment of Cushing syndrome discussed how cortisol-lowering therapies are monitored and adjusted in practice (PMID 41489578). Real-life data on pasireotide in monotherapy or in combination for active Cushing's disease reported outcomes when the drug was used outside controlled trial conditions (PMID 41323967). A 2023 review compared pasireotide with adrenal steroidogenesis inhibitors and other options, noting that each class carries a distinct safety trade-off (PMID 36927238).

Cardiac Rate and Conduction: What Studies Report

Publications covering the somatostatin-analogue class describe heart-rate and repolarisation considerations as part of routine safety assessment, and the pasireotide pharmacology review addressed the drug's profile in this context (PMID 29595102). The long-term acromegaly study reported safety across extended exposure, which is the setting in which such events would accrue (PMID 34081309), and the randomised Japanese phase 2 study reported safety outcomes for the long-acting formulation (PMID 28592706).

Reported adverse-event domains at a glance

Long-term and real-world reports

Short trials capture early events; long-term studies capture what persists. Researchers reporting long-term safety and efficacy of long-acting pasireotide in acromegaly extended observation well beyond the core trial period and described the drug's tolerability across that duration (PMID 34081309). Separately, a 2025 real-life analysis reported on pasireotide used alone or combined with other agents in active Cushing's disease, a design that captures patients who would typically be excluded from randomised trials (PMID 41323967). Reviews summarising these bodies of work continue to describe the same core trade-off between hormonal control and metabolic adverse effects (PMID 39526050).

Pregnancy and Special Populations: What Studies Report

Data on pasireotide in pregnancy are limited. A review on the approach to acromegaly during pregnancy examined how medical therapy has been handled in this population and highlighted the constraints of the available evidence (PMID 36359512). For Cushing syndrome, a 2025 case report described adrenocorticotropin-dependent Cushing syndrome with osilodrostat exposure in early pregnancy, illustrating that much of the pregnancy literature in this field consists of single cases rather than trials (PMID 41267803). Practical recommendations for medical treatment of Cushing syndrome also address special clinical situations where controlled data are sparse (PMID 41489578). Where controlled human data are absent, that absence is the finding — it is not evidence of safety.

Animal and Veterinary Data

Pasireotide has also been studied outside human medicine. A veterinary study evaluated pasireotide for the medical management of feline hypersomatotropism, reporting on its use in cats with growth-hormone excess (PMID 25945588). Findings in cats describe feline physiology and do not establish human safety outcomes; human adverse-event profiles are drawn from the clinical trials and cohorts cited above (PMID 34081309).

What the literature does not settle

• Individual risk prediction. Reviews describe group-level adverse-event patterns rather than who will experience them; the 2023 pharmacological evaluation framed drug selection in Cushing's disease as a comparative trade-off rather than a fixed rule (PMID 36927238).
• Pooled event rates. A protocol for a systematic review and meta-analysis of pasireotide in Cushing's disease was published precisely because pooled efficacy and safety estimates were not yet consolidated (PMID 33371162).
• Pregnancy outcomes. The acromegaly-in-pregnancy review reported that evidence in this setting remains limited (PMID 36359512).
• Non-approved uses. Standards-of-care guidance frames pasireotide within defined pituitary indications rather than general use (PMID 38833044).

Regulatory context

Pasireotide is a prescription medicine whose clinical development targeted pituitary disease; reviews of medical treatment for Cushing syndrome and standards of care for acromegaly describe it as part of the approved medical-therapy landscape in those indications (PMID 41489578, PMID 38833044). Research-use-only material sold for laboratory purposes is not an approved medicine and is not equivalent to a licensed pharmaceutical product.

Related learning

For background on what pasireotide is, how its receptor binding was characterised and which conditions it was developed for, the PeptideU pasireotide course covers the pharmacology and trial history in depth. This page deliberately stays on the safety and adverse-event literature so the two do not repeat each other.

References

• Update and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome (Endocrine Reviews, 2026)
• New Trends in Treating Cushing's Disease (TouchREVIEWS in Endocrinology, 2024)
• Long-term safety and efficacy of long-acting pasireotide in acromegaly (Endocrine, 2021)
• Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (Pituitary, 2024)
• A Case of Adrenocorticotropin-dependent Cushing Syndrome with Osilodrostat Exposure in Early Pregnancy (JCEM Case Reports, 2025)
• Pasireotide - Mechanism of Action and Clinical Applications (Current Drug Metabolism, 2018)
• Pasireotide for the Medical Management of Feline Hypersomatotropism (Journal of Veterinary Internal Medicine, 2015)
• Real-life data on pasireotide in monotherapy or combined in active Cushing's disease (Frontiers in Endocrinology, 2025)
• Efficacy and safety of pasireotide for Cushing's disease: A protocol for systematic review and meta-analysis (Medicine, 2020)
• Approach of Acromegaly during Pregnancy (Diagnostics, 2022)
• Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study (Endocrine Journal, 2017)
• An evaluation of pharmacological options for Cushing's disease: what are the state-of-the-art options? (Expert Opinion on Pharmacotherapy, 2023)